|
|
| | Vasonatrin Peptide (VNP)
Basic information |
| Product Name: | Vasonatrin Peptide (VNP)
| | Synonyms: | GLY-LEU-SER-LYS-GLY-CYS-PHE-GLY-LEU-LYS-LEU-ASP-ARG-ILE-GLY-SER-MET-SER-GLY-LEU-GLY-CYS-ASN-SER-PHE-ARG-TYR ((DISULFIDE BRIDGE: CYS6-CYS22);H-Gly-Leu-Ser-Lys-Gly-Cys-Phe-Gly-Leu-Lys-Leu-Asp-Arg-Ile-Gly-Ser-Met-Ser-Gly-Leu-Gly-Cys-Asn-Ser-Phe-Arg-Tyr-OH;L-Tyrosine, glycyl-L-leucyl-L-seryl-L-lysylglycyl-L-cysteinyl-L-phenylalanylglycyl-L-leucyl-L-lysyl-L-leucyl-L-α-aspartyl-L-arginyl-L-isoleucylglycyl-L-seryl-L-methionyl-L-serylglycyl-L-leucylglycyl-L-cysteinyl-L-asparaginyl-L-seryl-L-phenylalanyl-L-arginyl-, cyclic (6→22)-disulfide;Vasonatrin Peptide (VNP) Trifluoroacetate;Vasonatrin Peptide (VNP) | | CAS: | 141676-35-9 | | MF: | C124H198N36O36S3 | | MW: | 2865.32 | | EINECS: | | | Product Categories: | | | Mol File: | 141676-35-9.mol |  |
| | Vasonatrin Peptide (VNP)
Chemical Properties |
| density | 1.47±0.1 g/cm3(Predicted) | | Sequence | Gly-Leu-Ser-Lys-Gly-Cys-Phe-Gly-Leu-Lys-Leu-Asp-Arg-Ile-Gly-Ser-Met-Ser-Gly-Leu-Gly-Cys-Asn-Ser-Phe-Arg-Tyr (Disulfide bridge: Cys6-Cys22) |
| | Vasonatrin Peptide (VNP)
Usage And Synthesis |
| Uses | Vasonatrin Peptide (VNP) is a chimera of atrial natriuretic peptide (ANP) and C-type natriuretic peptide (CNP). Vasonatrin peptide possesses the venodilating actions of CNP, the natriuretic actions of ANP, and unique arterial vasodilating actions not associated with either ANP or CNP. Vasonatrin Peptide protects the diabetic heart against ischemia-reperfusion injury by inhibiting ER stress via the cGMP-PKG signaling pathway[1][2][3]. | | in vivo | Vasonatrin peptide (100 μg/kg; i.v. ; 10 min before reperfusion) attenuates myocardial ischemia-reperfusion injury in diabetic rats[3]. | Animal Model: | High-fat diet-fed streptozotocin-induced diabetic Sprague-Dawley rats[3] | | Dosage: | 100 μg/kg | | Administration: | I.v. ; 10 min before reperfusion | | Result: | Significantly improved the instantaneous first derivation of left ventricle pressure (±LV dP/dtmax) and LV systolic pressure and reduced LV end-diastolic pressure, apoptosis index, caspase-3 activity, plasma creatine kinase (CK), and lactate dehydrogenase (LDH) activities. Inhibited endoplasmic reticulum (ER) stress by suppressing glucose-regulated protein 78 (GRP78) and C/EBP homologous protein (CHOP).
|
| | References | [1] Wei CM, et al. Vasonatrin peptide: a unique synthetic natriuretic and vasorelaxing peptide. J Clin Invest. 1993;92(4):2048-2052. DOI:10.1172/JCI116800
[2] Chen BY, et al. Vasonatrin peptide, a new regulator of adiponectin and interleukin-6 production in adipocytes. J Endocrinol Invest. 2011;34(10):742-746. DOI:10.3275/7727
[3] Shi Z, et al. Vasonatrin peptide attenuates myocardial ischemia-reperfusion injury in diabetic rats and underlying mechanisms. Am J Physiol Heart Circ Physiol. 2015;308(4):H281-H290. DOI:10.1152/ajpheart.00666.2014 |
| | Vasonatrin Peptide (VNP)
Preparation Products And Raw materials |
|